Prostate cancer preferentially metastasizes to bone, leading to pain, spinal cord compression, and pathologic fractures in 75% to 80% of men with advanced disease. In addition, androgen deprivation therapy may accelerate bone loss and hasten skeletal complications.

In a discussion designed for oncologists and urologists, our panel of thought leaders will present the latest data on treatment options for advanced prostate cancer and the role of bisphosphonates in reducing skeletal complications. As a result of this discussion, you will be able to identify prostate cancer patients who are at risk for developing skeletal complications and understand the mechanisms of action by which bisphosphonates minimize skeletal complications in these patients.

Most importantly, you will be armed with the clinical data necessary to devise multidisciplinary strategies for maintaining bone health and prevent skeletal complications in your prostate cancer patients. We hope you join us for this informative webcast.

Sincerely,

top

DEVELOPMENT FACULTY

Co-Chairs

• Incorporate the latest data on innovations in therapy for hormone-refractory prostate cancer into treatment strategies to optimize outcomes.
• Identify patients with prostate cancer who are at risk for developing skeletal complications, including osteoporosis and fracture.
• Recognize the mechanisms of action by which bisphosphonates reduce morbidity from skeletal complications in prostate cancer patients.
• Compare the safety and efficacy profiles of bisphosphonate therapies when developing strategies to reduce the occurrence of skeletal complications in patients with advanced prostate cancer.
• Incorporate appropriate bisphosphonate therapy into individualized treatment plans to maintain bone health in patients with all stages of prostate cancer.

top

CME INFORMATION

DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that faculty participating in a CME activity disclose to the audience: any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation; any relationship with the commercial supporter of this activity; if discussion includes 1) therapies that are unapproved for use or are investigational; 2) ongoing research; or 3) preliminary data. Faculty will disclose such discussion.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

E. David Crawford, MD, is on the speakers bureau of and has received honoraria from AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, and TAP Pharmaceuticals Inc. Dr. Crawford has disclosed that he will discuss the investigational use of epothilones.

Arif Hussain, MD, has received grant/research support from Aventis Pharmaceuticals Inc, Bristol-Myers Squibb Company, Cytogen Corporation, Novartis Pharmaceuticals Corporation, and Pfizer Inc. Dr. Hussain has disclosed that he will discuss unlabeled/unapproved use of docetaxel.

James M. McKiernan, MD, is on the speakers bureau of Novartis Pharmaceuticals Corporation. Dr. McKiernan has disclosed that he will discuss investigational use of zoledronic acid/bisphosphonates.

Matthew R. Smith, MD, PhD, is a consultant for and has received grant/research support from Novartis Oncology. Dr. Smith will not be discussing unlabeled/unapproved use of any drug or device.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.

Peer Review process provided by the University of Pennsylvania School of Medicine Office of CME. To find out more information click here.

Release Date:
February 7, 2005.

Termination Date:
February 7, 2006.
Estimated Time for Completion of this Activity:
1 hour.

This independent CME activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

This activity is designed for medical oncologists and urologists who care for prostate cancer patients.

ACTIVITY GOAL

The goal of Innovations in Prostate Cancer Management is to present the latest data on treatment options for advanced prostate cancer and the role of bisphosphonates in minimizing skeletal complications in these patients.